VIRIOS THERAPEUTICS
Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. The company is driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions. The overactive immune response related to activation of tissue-resident Herpes Simplex Virus-1 (HSV-1) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatig... ue syndrome (CFS), and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of the disease. Virios Therapeutics' IMC-1, is a combination of antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral-mediated disease burden. In a Phase 2a proof-of-concept trial for fibromyalgia, IMC-1 provided statistically significant improvement versus placebo in the primary endpoint of pain reduction. The company plans to enter a Phase 2b trial in the 1Q21, with topline data expected in the 1Q22. Virios Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.
VIRIOS THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Mobile Apps Therapeutics
Founded:
2012-01-01
Address:
Alpharetta, Georgia, United States
Country:
United States
Website Url:
http://www.virios.com
Total Employee:
1+
Status:
Active
Contact:
866-620-8655
Email Addresses:
[email protected]
Total Funding:
6.24 M USD
Technology used in webpage:
Font Awesome Domain Not Resolving
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing novel T cell engagers (TriTACs) for the treatment of cancer.
Juventas Therapeutics
Juventas Therapeutics is a clinical-stage biotechnology company developing regenerative therapies to treat life threatening diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Current Employees Featured
Founder
Stock Details
Investors List
William Buchalter
William Buchalter investment in Seed Round - Virios Therapeutics
Official Site Inspections
http://www.virios.com Semrush global rank: 5.04 M Semrush visits lastest month: 1.64 K
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.171
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Virios Therapeutics" on Search Engine
Virios Therapeutics | Exploring New Treatment Paradigm for …
ABOUT VIRIOS. Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident ...See details»
Virios Therapeutics Announces Publication of International Patent …
Mar 26, 2024 Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID. - New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally –. - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation -.See details»
Virios Therapeutics Announces Plans to Advance Development …
ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced plans for advancing IMC-2 ...See details»
Virios Therapeutics Announces Plans to Advance Lead
ATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...See details»
Virios Therapeutics, Inc. Reaches Alignment with FDA on …
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...See details»
Virios Therapeutics Announces Plans to Advance Development …
ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...See details»
Virios Therapeutics, Inc. Reaches Alignment with FDA on
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on developing novel antiviral therapies to...See details»
Virios Therapeutics | LinkedIn
Virios Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal...See details»
Virios Therapeutics Announces Research Collaboration Exploring …
Feb 28, 2022 ATLANTA-- ( BUSINESS WIRE )-- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases,...See details»
Virios Therapeutics Announces Positive Data Demonstrating …
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...See details»
Virios Therapeutics Announces First Quarter 2024 ... - Morningstar
May 9, 2024 As of March 31, 2024, Virios Therapeutics’ cash totaled $2.4 million. The Company believes it will have sufficient resources to fund operations into the fourth quarter of 2024. About Virios ...See details»
Virios Therapeutics Announces Plans to Advance - GlobeNewswire
ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...See details»
Virios Therapeutics - Crunchbase Company Profile & Funding
Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. Alpharetta, Georgia, United States. 51-100. Post-IPO Equity. Public. www.virios.com/ 58,262. Stock Symbol NASDAQ:VIRI. Total Funding Amount. Unlock for free. Contacts 6. Employee Profiles 4. Investors 1.See details»
Virios Therapeutics Announces Research Collaboration Exploring …
Feb 28, 2022 ATLANTA-- (BUSINESS WIRE)-- Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today a collaboration with the Bateman Horne Center (“BHC”) of Salt Lake City, Utah, to explore the role of …See details»
Investor Relations :: Virios Therapeutics, Inc. (VIRI)
Company Overview. Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”).See details»
Virios Therapeutics Announces First Quarter 2024 Financial …
May 9, 2024 Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus …See details»
Virios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call Transcript
6 days ago SA Transcripts. 146.67K Follower s. Virios Therapeutics, Inc. ( NASDAQ: VIRI) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET. Company Participants. Angela Walsh - Senior Vice President of ...See details»
Earnings call: Virios Therapeutics reports on Q1 2024 progress
6 days ago Virios Therapeutics is making strides in their drug development programs, focusing on treatments for Long-COVID and fibromyalgia. The company's financial position allows them to operate into Q4 2024, and they are actively exploring strategic partnerships to further their research and development efforts. With ongoing clinical studies and a ...See details»
VIRI: Results for Phase 2 Long COVID Trial Expected in 2H24
By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Results from Ongoing Phase 2 Trial of IMC-2 in Long COVID Expected in 2H24 Virios Therapeutics, Inc. (NASDAQ:VIRI ...See details»
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call …
4 days ago Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript May 11, 2024 Virios Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Virios Therapeutics Incorporated First Quarter 2024 Earnings Call. …See details»